GlassScriptPhysician profile
Drew R Uhrig
NPI 1578829834
$33,604.61
in general payments reported to CMS, 2019-2025
77 companies · $4,045 in 2025
The $4,045 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,511 · 2020: $3,736 · 2021: $5,236 · 2022: $5,453 · 2023: $4,756 · 2024: $6,868 · 2025: $4,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $20.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,648.82 |
| Education | $20.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,138.25 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Novartis Pharmaceuticals Corporation | $2,337.44 | 2019-2025 | |
| Ucb, INC. | $2,034.62 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $1,500.88 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Alexion Pharmaceuticals, INC. | $1,268.45 | 2019-2025 | Ultomiris, Soliris |
| Lundbeck LLC | $1,160.39 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $1,052.99 | 2019-2025 | Uplizna, Aimovig |
| Pfizer INC. | $1,051.04 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,049.58 | 2020-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $1,041.60 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Acorda Therapeutics, INC | $1,022.41 | 2019-2024 | Inbrija |
| Allergan, INC. | $1,005.27 | 2019-2022 | |
| Mdd US Operations, LLC | $873.82 | 2019-2024 | Gocovri, Apokyn, Gocovri |
| Genentech USA, INC. | $867.76 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $829.11 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Uhrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.